Xilio Therapeutics, Inc.
A clinical-stage biotech developing tumor-activated immuno-oncology therapies for cancer.
XLO | US
Overview
Corporate Details
- ISIN(s):
- US98422T1007
- LEI:
- Country:
- United States of America
- Address:
- 828 WINTER STREET, 2451 WALTHAM
- Website:
- https://xiliotx.com/
Description
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes a proprietary, clinically validated platform to engineer biologics, including antibodies, masked bispecifics, and T cell engagers. These molecules are designed to be 'masked' or inactive in systemic circulation and become fully active only within the tumor microenvironment. This approach aims to concentrate the therapeutic effect precisely on the tumor, thereby minimizing systemic toxicity and improving the efficacy-to-toxicity ratio of potent immunotherapies. Xilio's pipeline consists of multiple clinical and preclinical programs designed to deliver powerful cancer treatments to a broader patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Xilio Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xilio Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xilio Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
